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Abstract
 
Allergic asthma is characterized by airway hyperresponsiveness, eosinophilia, and mucus ac-
cumulation and is associated with increased IgE concentrations. We demonstrate here that
peroxisome proliferator–activated receptors (PPARs), PPAR-
 
 
 
 and PPAR-
 
 
 
, which have
been shown recently to be involved in the regulation of various cell types within the immune
system, decrease antigen-induced airway hyperresponsiveness, lung inflammation, eosinophilia,
cytokine production, and GATA-3 expression as well as serum levels of antigen-specific IgE in
a murine model of human asthma. In addition, we demonstrate that PPAR-
 
 
 
 and -
 
 
 
 are ex-
pressed in eosinophils and their activation inhibits in vitro chemotaxis and antibody-dependent
cellular cytotoxicity. Thus, PPAR-
 
 
 
 and -
 
 
 
 (co)agonists might be of therapeutic interest for
the regulation of allergic or inflammatory reactions by targeting both regulatory and effector
cells involved in the immune response.
Key words: nuclear receptors • asthma • eosinophils • IgE • ADCC
 
Introduction
 
Allergic asthma is typically associated with airway hyperre-
sponsiveness (AHR),
 
*
 
 recruitment of inflammatory cells, in
particular eosinophils, and mucus accumulation due to
goblet cell metaplasia in the lung epithelium (1). These
functional and anatomical changes are also associated with
increased IgE production due to the development of a
strong Th2 response, mainly characterized by the produc-
tion of IL-4, IL-5, and IL-13 (1, 2).
Eosinophils are recruited from bone marrow and differ-
entiated within tissues upon activation by IL-5 and eotaxins
(CCL11, 24 and 26) binding to their specific receptors
(IL-5 R and CCR3). After their recruitment at inflamma-
tory sites, eosinophils are activated through various recep-
tors, among them immunoglobulin receptors, in particular
for IgE and monomeric or secretory IgA. Activation leads
to the release of cytotoxic mediators, such as eosinophil
peroxidase, eosinophil cationic protein, and major basic
protein, generating radical oxygen species, which together
are able to damage nonself targets such as parasites, larvae,
and bacteria but also self targets such as pulmonary epithe-
lial, cardiac, or nervous cells (3).
Most of inflammatory reactions lead to the activation of
NF-
 
 
 
B through several interconnected pathways. Among
the various regulators affecting these signaling cascades,
some nuclear receptors such as the peroxisome prolifera-
tor–activated receptors (PPARs) have been identified.
PPARs are ligand-activated transcription factors, belonging
to the nuclear receptor superfamily, that form dimers with
the retinoid X receptors (for review see reference 4). Three
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Abbreviations used in this paper:
 
 ADCC, antibody-dependent cellular
cytoxicity; AHR, airway hyperresponsiveness; BAL, bronchoalveolar la-
vage; LTB
 
4
 
, leukotriene B
 
4
 
; PAS, periodic acid schiff; PPAR, peroxisome
proliferator–activated receptor; RT, reverse transcriptase; WT, wild-type. T
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PPAR subtypes (
 
 
 
, 
 
 
 
/
 
 
 
, and 
 
 
 
) have been identified (4).
These receptors are activated by fatty acid and metabolites
such as leukotriene B
 
4
 
 (LTB
 
4
 
), which is preferentially
bound by PPAR-
 
 
 
 (5). PPAR-
 
 
 
/
 
 
 
 binds prostacyclin
(prostaglandin I
 
2
 
 or PGI
 
2
 
; reference 6), whereas PPAR-
 
 
 
is activated by some eicosanoids: 13-hydroxyoctadecadi-
enoic acid (7), 15-hydroxyeicosatetraenoic acid and 15-
deoxy-
 
 
 
12,14
 
-prostaglandinJ2 (15d-PGJ
 
2
 
; reference 8), a
prostaglandin D2 metabolite. Both PPAR-
 
 
 
 and PPAR-
 
 
 
have been shown to negatively regulate inflammation and
to play a role within the immune system, (9–11) acting on
T lymphocytes (12, 13), monocytes/macrophages (14–18),
dendritic cells (19), and mast cells (20). Besides its role in
skin wound healing and keratinocyte proliferation, little is
known about the role of PPAR-
 
 
 
/
 
 
 
 in the control of in-
flammation (21).
In vivo, PPAR-
 
 
 
 has been shown to decrease the sever-
ity of colitis in two experimental models (22, 23): arthritis
and IgM production (24). Furthermore, PPAR-
 
 
 
 agonists
have been tested with some success as a potential therapy
for ulcerative colitis (25). In humans, PPAR-
 
 
 
 expression
is increased in bronchial submucosa, airway epithelium,
and smooth muscle cells from asthmatic patients (26).
PPAR-
 
 
 
–deficient mice display prolonged LTB
 
4
 
-induced
ear swelling (5), absence of regulation of spontaneous
proinflammatory cytokine production upon aging (27), and
exacerbated response of aortic explants to proinflammatory
stimuli (28).
In this paper, we aimed at determining whether PPAR-
 
 
 
and -
 
 
 
 also act as modulators of asthma and lung inflamma-
tion associated with prominent eosinophilia, and whether
they would directly affect eosinophil function.
 
Materials and Methods
 
Animals.
 
PPAR-
 
 
 
–deficient mice, originally obtained from
Dr. F.J. Gonzalez (National Institutes of Health, Bethesda, MD;
reference 29), and corresponding wild-type (WT) 129S1/SVImJ
were purchased from Jackson ImmunoResearch Laboratories and
bred within the specific pathogen-free facility from the Institut
Pasteur de Lille. Balb/c animals were purchased from Iffa-Credo.
Hypereosinophilic IL-5 
 
 
 
 hFc
 
 
 
RI
 
 
 
Tg mice have been produced
in our laboratory and described previously (30). 8–12-wk-old fe-
male mice were used for all the experiments. LouM rats were
produced at the Institut Pasteur de Lille.
 
Asthma Model.
 
Mice were sensitized with OVA (50 
 
 
 
g in
100 
 
 
 
l Alum–Imject™; Pierce Chemical Co.) or received Alum
only and were challenged for 20 min on days 14, 15, 18, 19, and
20 by aerosol nebulization with OVA (1% in PBS) using an ultra-
sonic nebulizer (Systam). For some experiments, 5 
 
  
 
10
 
 
 
5
 
 M
ciglitazone (Qbiogene) or 5 
 
  
 
10
 
 
 
5
 
 ciglitazone M and 5 
 
  
 
10
 
 
 
5
 
 M
GW9662 (Cayman) in PBS (or vehicle) were administered to
Balb/c mice by nebulization for 20 min immediately before and
during each OVA sensitization. Serum was collected on day 21
and AHR (enhanced Pause) to increasing concentrations of
methacholine (1.5–12 mg/ml) was measured by whole-body
plethysmography (Emka) on day 22 (31). Lungs were used either
for bronchoalveolar lavages (BALs) and protein extraction or for
histological analyses and protein extraction.
 
For histology, lung samples were fixed with Immunohisto-
fix™ and embedded in Immunohistowax™ (Universite Libre
de Bruxelles). 4-
 
 
 
m sections were stained either with May
Grünwald Giemsa or periodic acid schiff (PAS) for detection of
mucopolysaccharide accumulation. Cellular content of BAL was
analyzed on cytospin preparations after staining with May Grün-
wald Giemsa.
Quantification of cytokines in lung tissue was performed
as described previously (32, 33). In brief, samples were ho-
mogenized, using an Ultra-turrax, in 400 
 
 
 
l of buffer (per
right lung) containing 1% NP-40, 150 mM NaCl, 50 mM
Hepes, PMSF, and Complete protease inhibitor cocktail
(Roche). IL-4, IL-5, IL-6, IL-13, eotaxin/CCL11, and solu-
ble VCAM-I were measured using specific ELISA kits (R&D
Systems).
Serum anti-OVA IgG
 
1
 
 was measured by ELISA, using OVA-
coated plates and HRP-conjugated anti–mouse IgG
 
1
 
 (Southern
Biotechnology Associates, Inc.). Serum anti-OVA IgE was mea-
sured by ELISA using anti-IgE (BD Biosciences) as capture anti-
body and biotinylated OVA and HRP-conjugated streptavidin
(Amersham Biosciences) for detection. Twofold serial dilutions
were prepared for each serum (starting dilution 1:25 for IgE and
1:5,000 for IgG
 
1
 
 titrations). Antibody titers were calculated as the
dilution corresponding to twice the mean absorbance value ob-
tained for nonsensitized mouse sera.
 
Eosinophil Purification.
 
Human eosinophils were isolated,
from the venous blood of hypereosinophilic patients (eosinophilia
associated with skin diseases or allergy), by negative selection us-
ing anti–CD16- and anti–CD3-coated magnetic beads and
MACS system (Miltenyi Biotec), as described previously (34).
Eosinophil purity 
 
 
 
97%.
Mouse eosinophils were obtained from spleens from naive
IL-5 
 
 
 
 hFc
 
 
 
RI
 
 
 
 Tg mice and purified by negative selection, us-
ing CD90 (Thy1.2), CD45R (B220), and CD8
 
 
 
 (Ly-2) magnetic
beads for depletion, as described previously (35). Typical purity
was 95–97%.
Rat eosinophils were obtained by lavage of the peritoneal cav-
ity from naive LouM rats. Eosinophils were purified by negative
selection using anti-CD45R, anti-CD8
 
 
 
, and antimononuclear
phagocyte (1C7) antibodies to remove B cells, T cells, and mac-
rophages. Typical purity was 90%.
 
Reverse Transcriptase (RT)–PCR.
 
Total RNA was isolated us-
ing RNAplus (Qbiogene). Reverse transcription was performed
with 2 
 
 
 
g RNA using SuperScript™ RT (GIBCO BRL, Life
Technologies). cDNA was amplified using various primers as
follows: human PPAR-
 
 
 
 (5
 
 
 
-ATGAGGCCATATTCGCCA-
TGC-3
 
 
 
 and 5
 
 
 
-GTTGCTCTGCAGGTGGAGTCT-3
 
 
 
); mouse/
rat PPAR-
 
 
 
 (5
 
 
 
-CGGCCTGGCCTTCTAAACATAGGC-3
 
 
 
and 5
 
 
 
-CAGTGGGTGCAGCGCTGCGTCGGACTCGGTC-
3
 
 
 
); human PPAR-
 
 
 
 (5
 
 
 
-GCCTTGCAGTGGGGATG-
TCTCA-3
 
 
 
 and 5
 
 
 
-GATGCGGATGGCCACCTCTTT-3
 
 
 
);
mouse PPAR-
 
 
 
 (5
 
 
 
-TCTCTCCGTAATGGAAGACC-3
 
 
 
 and
5
 
 
 
-GCATTATGAGACATCCCCAC-3
 
 
 
); rat PPAR-
 
 
 
 (5
 
 
 
-
GGCGAGGGCGATCTTGACAGG-3
 
 
 
 and 5
 
 
 
-AGGGCTTC-
CGCAGGCTTTTGA-3
 
 
 
); human 
 
 
 
-actin (5
 
 
 
-GGGTCAGA-
AGGATTCCTATG-3
 
 
 
 and 5
 
 
 
-GGTCTCAAACATGATCT-
GGG-3
 
 
 
); and mouse 
 
 
 
-actin (5
 
 
 
-GTCGGGCGCCCCA-
GGCACCA-3
 
 
 
 and 5
 
 
 
-CTCCTTAATGTCACGCACGAT-
TTC-3
 
 
 
).
PCR was run for 38–40 cycles (annealing: 54
 
 
 
C) using Taq
polymerase (Bioprobe). PCRs were performed on each sample
using 
 
 
 
-actin–specific primers and analyzed on 2% agarose gels
after ethidium bromide staining. Gel loadings of the various am-T
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plified products were normalized according to the signal intensity
provided by the  -actin amplification. RNA prepared from
mouse liver and spleen, rat spleen, and HepG2 cells were used as
positive controls.
Western Blot. Protein extracts were prepared as described in
the Asthma Model section for the quantification of cytokines in
lung tissues by ELISA. 10- g proteins were loaded on a 10%
SDS-PAGE gel. Material was transferred onto nitrocellulose and
probed with rabbit anti–PPAR-  (RDI), anti–PPAR-  (BIO-
MOL Research Laboratories, Inc.), and anti–GATA-3 (Santa
Cruz Biotechnology, Inc.) specific antisera. Signals were detected
using peroxidase-conjugated antibody (Jackson ImmunoResearch
Laboratories) and Renaissance Western Plus (NEN Life Science
Products). Extracts from mouse liver and human adipose tissue
were used as positive controls for PPAR-  and - , respectively.
The pool of mediastinal LNs from OVA-sensitized and -chal-
lenged PPAR-  /  and Balb/c mice were used as positive con-
trols for GATA-3.
Flow Cytometry. 2   105 cells were fixed with 2% paraformal-
dehyde and permeabilized with 0.1% saponin in PBS, before in-
cubation in PBS-saponin with rabbit anti–PPAR-  (RDI), anti–
PPAR-  (Biomol), or corresponding control antisera for 30 min
in the presence of saponin. Nonspecific binding was blocked with
5  l goat serum for 10 min and FITC-conjugated goat anti–rab-
bit (Jackson ImmunoResearch Laboratories) was added to the
cells. Samples were analyzed on a FACSCalibur™ using the
CELLQuest™ software (Becton Dickinson).
Chemotaxis. Human eosinophil chemotaxis was assessed by a
modification of the Boyden micropore filter technique (36).
Eosinophils (5   104 cells/well) were incubated in quadruplicate
with WY14653 (Qbiogene), ciglitazone, rosiglitazone, GW9662,
or rosiglitazone and GW9662 (concentration range 10 8–10 5 M;
Cayman Chemical) or DMSO in the upper chamber sepa-
rated from the chemoattractant 10 ng/ml IL-5 or 1 ng/ml eo-
taxin by a 5- m pore size polycarbonate membrane filter (Nucle-
opore Co.). The numbers of eosinophils that had migrated after
2 h were enumerated microscopically. Results for each dose of ago-
nist were expressed as percentage of inhibition. Three to five in-
dependent experiments using cells from different donors were
performed for each agonist.
ADCC toward Schistosoma mansoni Larvae. Antibody-depen-
dent cellular cytoxicity (ADCC) experiments were performed as
described previously (37). Human or rat eosinophils (3   105
cells/well) were incubated overnight in medium containing
PPAR-  and -  agonists (concentration range 10 9–10 5 M) or
vehicle. Schistosomula ( 100 per well) were added to human or
rat eosinophils together with serum from S. mansoni–infected pa-
tients or rats, respectively. Schistosomula mortality was assessed
microscopically 48 h later on duplicated wells. Results for each
dose of agonist were expressed as percentage of inhibition.
Three to eight independent experiments using cells from differ-
ent donors or from different pools of rats were performed for
each agonist.
Statisitical Analysis. Statistical significance was determined us-
ing the Wilcoxon-signed rank test for paired groups for ADCC
and chemotaxis experiments. For animal experiments, unpaired
Student’s t tests were used except for Penh determination for
which ANOVA for repeated measures were used. P   0.05 were
considered as significant. Results of statistical analyses from in
vivo experiments are summarized in Table I.
Results
PPAR- –deficient Mice Exhibit Increased AHR and Eosino-
philia. The effect of PPAR- –deficiency on AHR was
studied in a murine model closely mimicking human
asthma. Indeed, upon sensitization by intraperitoneal injec-
tion of OVA in the presence of alum and challenge by re-
peated OVA nebulizations, mice develop lung inflamma-
tion characterized by eosinophilia, IgE production, and
increased AHR in response to methacholine provocation.
In this model, responses of WT (PPAR-  / ) 129S1/
SVImJ and PPAR- –deficient (PPAR-  / ) animals were
compared. AHR was measured by whole body plethys-
mography upon challenge with increasing doses of metha-
Table I. Statistical Analysis of In Vivo Experiments
P value
PPAR  /  OVA
versus
WT OVA
PPAR  /  OVA
versus
PPAR  /  Alum
WT OVA
versus
WT Alum
Cigli. 
versus
OVA
Cigli. 
versus
Cigli.   GW
OVA 
versus
control
Penh  0.0001  0.0001  0.0001 0.003  0.014 0.007
BAL (total cells)  0.0001  0.0001 0.009 0.004  0.05 0.0007
BAL (eosinophils)  0.0001  0.0001 0.006 0.003  0.019 0.0005
Anti-OVA IgE  0.033 ND ND 0.003  0.048 ND
Anti-OVA IgG1 NS ND ND 0.004 NS ND
IL-4 NS NS NS 0.021  0.012 0.0002
IL-5 NS NS NS 0.006 0.0006  0.0001
IL-6  0.034 NS NS 0.0007  0.002  0.0001
IL-13 0.05 NS NS 0.009  0.003 0.007
Eotaxin 0.011  0.0001 0.007 NS NS NS
sVCAM-1 NS NS NS NS NS NS
Unpaired t test was used for all parameters except Penh, for which ANOVA for repeated measures was used. NS, not significant; ND, not determined.T
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choline (results were expressed as the enhanced pause-Penh
values). OVA-sensitized and -challenged PPAR- –defi-
cient animals displayed a 2.4-fold higher response (for 6
mg/ml methacholine) compared with their WT counter-
parts (Fig. 1 a). Indeed, sensitization led to a 6.8-fold Penh
increase in PPAR- –deficient animals, whereas it only led
to a 2.2-fold increase in WT animals. After sensitization
and airway antigen challenge, the overall inflammatory in-
filtrate in the BALs and the total number of eosinophils
were greatly increased (4.7- and 5.3-fold, respectively) in
PPAR- –deficient animals, compared with WT animals
(Fig. 1 b).
Histological examination of the lung confirmed that,
upon sensitization and challenge, PPAR- –deficient ani-
mals displayed more pronounced inflammation with con-
spicuous peribronchial and perivascular eosinophilia (Fig. 1
c and inset) than the corresponding WT animals (Fig. 1 d).
As reported previously for this asthma model (38), eosino-
phils did not show evidence of degranulation. PAS staining
also revealed increased mucus accumulation in the bron-
chial lumen from PPAR- –deficient mice compared with
WT animals (unpublished data). Neither strain was exhibit-
ing an inflammatory phenotype in the absence of sensitiza-
tion (Fig. 1, e and f).
The humoral Th2 response characteristic of asthmatic
reactions was also affected in PPAR- –deficient mice. In-
deed, serum levels of OVA-specific IgE were increased
3.5-fold in PPAR- –deficient mice compared with WT
animals (Fig. 2 a, left). Levels of specific IgG1, also associ-
ated with a Th2 response, were increased 1.5-fold in
PPAR- –deficient mice (not statistically significant; Fig. 2
a, right).
Increased lung inflammation, eosinophilia, and IgE
production from PPAR- –deficient mice were locally as-
sociated with higher levels of proinflammatory cytokine
IL-6, eosinophil chemoattractant eotaxin, and IgE-induc-
ing IL-13 in lung extracts compared with tissue from WT
animals (Fig. 2 b). By contrast, no differences were ob-
served for IL-4 and IL-5 nor for sVCAM-1 (unpublished
data). Immunohistological detection of VCAM-1 and
ICAM-1 in the lung of PPAR- –deficient and WT ani-
mals did not reveal any differences (unpublished data).
Furthermore, after antigen sensitization and challenge, ex-
pression of GATA-3, a transcription factor essential for
Th2 polarization (39) and expressed in lung eosinophils
upon antigen sensitization (40), was greatly increased in
lung extracts from PPAR- –deficient mice compared
with tissues from WT animals, where expression is virtu-
ally nondetectable (Fig. 2 c). This reflects an enhanced
recruitment of cells involved in the Th2 response at the
tissular inflammatory site. Together, these results demon-
strate that the absence of PPAR-  exacerbates asthmalike
reactions and eosinophilia.
PPAR-  Activation Reduces AHR and Eosinophilia. Be-
cause the complete inactivation of the PPAR-  gene leads
to embryonic lethality, the PPAR-  agonist ciglitazone
was used to investigate the potential role of PPAR-  as a
regulator of airway inflammation. Ciglitazone was targeted
to the airways by nebulization immediately before and dur-
ing OVA sensitization. Agonist administration to Balb/c
mice led to a decreased AHR compared with untreated
OVA-sensitized animals (Fig. 3 a), which was accompanied
by a decreased eosinophilia in BAL (1.9-fold; Fig. 3 b). Eo-
sinophilia was also reduced in lung tissue after ciglitazone
Figure 1. Increased asthma-like reactions in PPAR-  /  mice. (a)
AHR of OVA-sensitized and -challenged or unsensitized but challenged
PPAR-  /  or corresponding WT animals to increasing methacholine
concentrations 48 h after the last OVA nebulization. (b) Cellularity and
eosinophilia in BALs at the time of sacrifice. (n    4–13 animals per
group. Data expressed as mean   SEM; some bars may fall within mark).
§, Statistically different from OVA-sensitized and aerosol-challenged WT
animals.  , Statistically different from unsensitized but aerosol challenged
PPAR-  /  mice. $, Statistically different from unsensitized but aerosol
challenged WT mice (see Table I for P values). (c–f) May Grünwald Gi-
emsa staining of lung sections from OVA-sensitized and aerosol-challenged
(c and d) or unsensitized but aerosol-challenged (e and f) PPAR-  /  (c
and e) or WT (d and f) mice (original magnification 100). Inset: arrows
indicate eosinophils (original magnification 400).T
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treatment (Fig. 3 c). Mucus accumulation in the airways
evidenced by PAS staining was likewise diminished by cig-
litazone (unpublished data). Importantly, the inhibitory ef-
fects of ciglitazone treatment on AHR were abrogated
when GW9662, a PPAR- –specific antagonist, was ad-
ministered concomitantly with the agonist (Fig. 3 a), thus
demonstrating that ciglitazone was mainly acting through
PPAR-  in this model. Indeed, GW9662 also significantly,
albeit only partially, reverted inhibition of cellular recruit-
ment and eosinophilia in BAL and lung tissue after ciglita-
zone treatment (Fig. 3, b and c).
Furthermore, ciglitazone reduced serum levels of OVA-
specific IgE and IgG1 2.5- and 9.8-fold, respectively (Fig.
4 a). Cytokines associated with inflammation (IL-6), eo-
sinophilia (IL-5), and Th2-driven humoral immune re-
sponses (IL-4 and IL-13) were also decreased in lung ex-
tracts (Fig. 4 b), whereas eotaxin and sVCAM-1 were not
affected (unpublished data). Likewise, ciglitazone treat-
ment very effectively decreased the amount of GATA-3
protein present in lung extracts, reflecting inhibition of lo-
cal Th2 response (Fig. 4 c). With the exception of OVA-
specific IgG1 production, GW9662 treatment reverted the
inhibitory effects of ciglitazone on these parameters, in
particular on IL-5 and IgE production (Fig. 4, a–c). Thus,
administration of a PPAR-  agonist during antigen chal-
lenge periods decreased most of the characteristic parame-
ters of airway inflammation.
PPAR-  and -  Are Expressed by Eosinophils. To deter-
mine whether the observed effects of PPAR-  and -  on
eosinophilia in vivo may be in part related to a direct mod-
ulation of eosinophil activation, PPAR expression was ana-
lyzed in eosinophils in vitro. PPAR-  and -  expression
was assessed in highly purified eosinophils from three dif-
ferent species (human, mouse, and rat) using three inde-
pendent techniques.
Specific transcripts for PPAR-  (Fig. 5 a, top) and, at a
lower level, for PPAR-  (Fig. 5 a, middle) were detected
by RT-PCR in mouse (purity   95%), rat (purity  
90%), and human (purity   97%) eosinophils. These re-
sults were confirmed at the protein level by Western blot
analysis (Fig. 5 b). To further exclude that the signal ob-
tained by RT-PCR or Western blot was due to a minor
contamination with another cell type highly expressing
these PPARs, we performed flow cytometry analyses on
permeabilized cells using a narrow gating on eosinophil
populations, which display a very characteristic scatter
pattern (small highly granular cells). Indeed, both PPAR- 
and -  were expressed in the gated cells from mouse,
rat, and human eosinophil preparations (Fig. 5 c, top left
and bottom). Finally, PPAR-  and -  expression levels
were investigated in eight eosinophilic patients. PPAR- 
expression was homogenous, whereas PPAR-  expres-
sion was present at more variable levels between individ-
uals (Fig. 5 c top right), which suggests, as reported pre-
Figure 2. Increased lung inflam-
mation and humoral response in
PPAR-  /  mice. (a) Serum OVA-
specific IgE (left) and IgG1 (right)
from animals treated as in Fig. 1 24 h
after the last OVA nebulization. (b)
IL-6, -13, and eotaxin content from
lung extracts from animals treated as
in Fig. 1. (n     4–13 animals per
group. Data expressed as mean  
SEM; some bars may fall within
mark.)  §, Statistically different from
OVA-sensitized and aerosol-chal-
lenged WT animals.  , Statistically
different from unsensitized but aero-
sol-challenged PPAR-  /  mice. $,
Statistically different from unsensi-
tized but aerosol-challenged WT
mice (see Table I for P values). (c)
Western blot analysis of GATA-3
expression in lung extracts (and
lymph nodes [L. Node]) from indi-
vidual animals treated as in Fig. 1.T
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viously (26), that PPAR-  may indeed be regulated by
some factors associated with the pathology. No correla-
tion was found between PPAR expression and the activa-
tion state of eosinophils, as evaluated by serum eosinophil
cationic protein and CD25 measurements (unpublished
data).
PPAR-  and -  Activation Inhibits Eosinophil Chemo-
taxis. To establish whether PPAR-  and -  agonists di-
rectly modulate eosinophil chemotactic response to IL-5 or
eotaxin, two potent physiological chemoattractants, we
performed in vitro chemotaxis experiments with human
eosinophils. PPAR-  (WY14653) or PPAR-  (rosiglita-
zone) agonists were able to inhibit IL-5– and eotaxin-in-
duced eosinophil migration (Fig. 6, a and b). Similar results
were obtained with ciglitazone (unpublished data). The re-
quirement of PPAR-  for this inhibitory effect was con-
firmed by using GW9662. Indeed, eosinophil incubation
with GW9662 in conjunction with rosiglitazone led to a
virtually complete loss of chemotaxis inhibition (Fig. 6 a,
inset). Thus, PPAR-  and -  activation by specific agonists
can act directly on eosinophils and regulate their move-
ment, at least in vitro.
PPAR-  and -  Activation Inhibits Eosinophil-mediated Cy-
totoxicity. Upon activation with various antibody isotypes,
including IgA and IgE, both human and rat eosinophils are
able to develop cytotoxic properties against parasitic targets
in vitro associated with a protective immune response in
vivo. Measurement of eosinophil-dependent cytotoxicity is
thus a good in vitro correlate of their effector function in
Figure 3. Regulation of asthma-like reactions by PPAR- . Mice were
sensitized by intraperitoneal injection of OVA in alum and challenged by
repeated nebulizations of OVA together with nebulization with 5  
10 5 M ciglitazone, 5   10 5 M ciglitazone and 5   10 5 M GW9662
or vehicle. Unsensitized control animals received alum only and were
challenged with OVA as for sensitized animals. (a) AHR to increasing
methacholine concentrations 48 h after the last nebulization. (b) Cellular-
ity and eosinophilia in BALs at the time of sacrifice. (n   4–8 animals per
group; data expressed as mean   SEM, some bars may fall within mark).
§: Statistically different from OVA-sensitized and aerosol-challenged ani-
mals.   : Statistically different from OVA-sensitized and aerosol-chal-
lenged mice treated with both ciglitazone and GW9662. $: Statistically
different from unsensitized but aerosol challenged mice (see Table I for
P values). (c) May Grünwald Giemsa staining of lung sections from sensi-
tized mice nebulized with OVA together with vehicle (upper left), with
5   10 5 M ciglitazone (upper right) or with 5   10 5 M ciglitazone and
5   10 5 M GW9662 (lower left) and from unsensitized animals (lower
right) (original magnification 100).
Figure 4. Regulation of pulmonary inflammation and humoral re-
sponse by PPAR- . (a) Serum OVA-specific IgE (left) and IgG1 (right)
from animals treated as in Fig. 3 24 h after the last OVA nebulization. (b)
IL-4, -5, -6, and -13 content of lung extracts from animals treated as in
Fig. 3. (n   4–19 animals per group. Data expressed as mean   SEM;
some bars may fall within mark.) §, Statistically different from OVA-sensi-
tized and aerosol-challenged animals.  , Statistically different from OVA-
sensitized and aerosol-challenged mice treated with both ciglitazone and
GW9662. $, Statistically different from unsensitized but aerosol-chal-
lenged mice (see Table I for P values). (c) Western blot analysis of
GATA-3 expression in lung extracts (and lymph nodes [L. Node]) from
individual animals treated as in Fig. 3.T
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vivo (41, 42). Therefore, the effects of PPAR-  and -  ag-
onists on eosinophil-mediated ADCC were investigated. A
dose-dependent inhibition of human eosinophil-mediated
ADCC was observed with rosiglitazone, ciglitazone, and
WY14653, with respective maximal inhibition of 45, 33,
and 28% (at 10 5 M; Fig. 6 c). Similar results were obtained
with rat eosinophils (Fig. 6 d). However, maximal inhibi-
tory effects for the three agonists were obtained at lower
concentrations (41, 44, and 39% at 10 7 M). Our results
demonstrate that both PPAR-  and PPAR-  agonists sig-
nificantly inhibit ADCC reactions mediated by human or
rat eosinophils.
Discussion
The regulatory role of PPAR-  and -  on allergic lung
inflammation and eosinophilia was investigated in vivo us-
ing a classical animal model for human asthma. This model,
Figure 5. PPAR expression in eosinophils. (a) RT-PCR amplification
of PPAR-  (top), PPAR-  (middle), and  -actin (bottom) mRNA from
human, mouse, and rat eosinophils. (top) Total WT mouse liver, rat peri-
toneal eosinophils, and eosinophils from IL-5 Tg mouse spleen (amplicon
size: 215 bp; left). HepG2 cells and human peripheral blood eosinophils
(amplicon size: 304 bp; right). (middle) Total WT mouse spleen and eosin-
ophils from IL-5 Tg mouse spleen (amplicon size: 473 bp; left). Total rat
spleen and rat peritoneal eosinophils (amplicon size: 343 bp; center).
HepG2 cells and human peripheral blood eosinophils (amplicon size: 337
bp; right). (bottom) Total WT mouse spleen, eosinophils from IL-5 Tg
mouse spleen, total WT mouse liver, total rat spleen, and peritoneal rat
eosinophils (amplicon size: 532 bp; left). Human peripheral blood eosino-
phils and HepG2 cells (amplicon size: 238 bp; right). (b) Identification of
PPAR-  (top) and PPAR-  (bottom) proteins in human and mouse
eosinophil lysates by Western blot analysis. Immunodetection of PPAR- 
and PPAR-  in cell lysates from IL-5 Tg mouse eosinophils and WT
mouse liver or human peripheral blood eosinophils from two different
donors and adipose tissue after SDS-PAGE and transfer on membrane. (c)
Detection of PPAR-  and PPAR-  by flow cytometry on permeabilized
human (top), mouse (bottom left), and rat eosinophils (bottom right).
Relative expression levels of PPAR-  and PPAR-  in eosinophils from
eight donors with hypereosinophilia (mean fluorescence intensity [MFI];
control rabbit IgG (rbIgG); average value is represented by the horizontal
bar in each group). On histogram plots, anti–PPAR-  (thin line), anti–
PPAR-  (thick line), control rabbit IgG (dotted line), and FITC-conju-
gated secondary antibody (dashed line).
Figure 6. Regulation of eosinophil function by PPAR in vitro. (a and
b) Inhibition of eosinophil chemotaxis by PPAR. Dose-dependent inhibi-
tion of IL-5– and eotaxin-induced chemotaxis of human peripheral blood
eosinophils by rosiglitazone (a) and WY14653 (b). P   0.0001 for each
agonist with both chemoattractants versus untreated cells. Inset: Abroga-
tion of rosiglitazone inhibition of IL-5–induced chemotaxis by GW9662
(concentration of each compound 10 5 M). (c and d) Inhibition of eosin-
ophil-mediated ADCC by PPAR agonists. Dose-dependent inhibition of
human (c) or rat (d) eosinophil-mediated ADCC toward S. mansoni larvae
by WY14653, ciglitazone, and rosiglitazone (n   3–8 independent exper-
iments; data expressed as mean   SEM). (1) and (5) P   0.0001 for rosi-
glitazone-treated versus vehicle-treated cells; (2) P   0.034 and (6) P  
0.0001 for ciglitazone-treated versus vehicle-treated cells; (3) P   0.037
and (4) P   0.0001 for WY14653-treated versus vehicle-treated cells.T
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in which both CD4  and CD8  T lymphocytes play an
important role (43, 44), is characterized by increased airway
hyperreactivity, eosinophilia, and high IgE concentrations.
Use of PPAR- –deficient mice allowed us to unequiv-
ocally demonstrate that the absence of PPAR-  led to in-
creased lung eosinophilia and AHR, which were accom-
panied by increased antigen-specific IgE concentrations
compared with WT animals. This increased functional,
cellular, and humoral response was correlated to increased
lung expression of GATA-3, associated with Th2 polariza-
tion (39), and to increased levels of the proinflammatory
cytokine IL-6 as well as IL-13 and eotaxin, two major fac-
tors promoting AHR, eosinophilia, and IgE production
(1, 45).
LTB4, a natural PPAR-  ligand (5), is abundantly pro-
duced, among other cell types, by mast cells in inflamma-
tory reactions such as asthma (46) and is highly chemotactic
for eosinophils that express a specific membrane LTB4 re-
ceptor: BLTR (35). Because PPAR-  activation by LTB4
leads to an anti-inflammatory response, the absence of
PPAR-  expression (in eosinophils and other cell types
from PPAR- –deficient mice) would exacerbate the che-
motactic response by creating an imbalance between stimu-
latory and inhibitory effects.
PPAR-  has been recently shown to negatively regulate
the Th1-inducing transcription factor T-bet (47). It might
also affect directly or indirectly GATA-3, the T-bet Th2
counterpart, which is not only expressed in Th2 cells (39)
but also in lung eosinophils (40). Thus, GATA-3 decreased
expression could be due to an effect on both cell types. Al-
though an inhibitory effect of PPAR-  has been reported
for IL-6 production by vascular tissues (28), this represents
the first paper demonstrating a regulation by PPAR-  of
eotaxin, an eosinophil chemotactic factor, and IL-13, an
IgE-inducing factor for B cells. IL-13 is produced mainly
by T cells, which express PPAR-  (13), and by eosinophils
themselves (48). This production is regulated by both IL-5,
another cytokine preferentially produced by Th2 cells, and
by eotaxin (49). Besides B cells, IL-13 affects airway epi-
thelial cells, where it is able to induce eotaxin production
(50) and to regulate AHR and mucus overproduction (51),
smooth muscle cells, and fibroblasts, which can also be trig-
gered to produce eotaxin, IL-6, and VCAM-1 (52). Addi-
tionally, PPAR-  might regulate IgE production through a
direct action on B cells, in which it is expressed (13). Fi-
nally, eotaxin is produced by endothelial cells (53), in
which PPAR-  is expressed (54). Hence, PPAR-  ago-
nists, at least in this latter cell type, might be able to modu-
late its expression.
In the same model of antigen sensitization and airway
challenge, we demonstrated that delivery of a PPAR- 
agonist to the lung, through nebulization, profoundly de-
creased AHR, IgE (and IgG1) production, and eosino-
philia, with a concomitant decrease of IL-4, IL-5, IL-6, IL-
13, and GATA-3 expression. According to the parameter
measured, this inhibitory effect was totally or partially abro-
gated by coadministration of a GW9662 an irreversible
PPAR-  antagonist, thus demonstrating that most ciglita-
zone-mediated effects indeed occur through PPAR- 
stimulation in this model.
PPAR-  appears to regulate IL-4 and IL-5, which pro-
mote AHR in conjunction with IL-13 (1), but not eotaxin
production. PPAR-  activation might also influence lung
infiltration by inflammatory cells and, among them, eosin-
ophils, which are responsive to IL-5. Furthermore, in ad-
dition to T cell function, PPAR-  is expressed in airway
epithelial, submucosal and smooth muscle cells and regu-
lates their function (26, 55, 56). Other likely targets for
PPAR-  are dendritic cells, whose activity is modulated by
PPAR-  (19, 57), and which play a key role in the induc-
tion of the pulmonary response to antigen inhalation (58).
Inhibition of dendritic cell migration by PPAR-  agonists,
as reported previously for prostaglandin D2 (59), a precur-
sor of 15d-PGJ2 (a natural PPAR-  ligand), would contrib-
ute to decreased eosinophilia as well as to decreased T cell
proliferation, which is also directly inhibited by PPAR- 
(24, 60). Finally, it has been shown in an arthritis model,
that PPAR-  hemizygous mice displayed increased B cell
and T cell proliferation and IgM production (24). A regula-
tion by PPAR-  agonists of IgE germline transcript syn-
thesis in vitro by a human B cell line was also reported (61).
In our in vivo model, PPAR-  agonists also regulate IgE
and IgG1 production in a secondary immune response.
The further demonstration that both PPAR-  and - 
are expressed by mouse, human, and rat eosinophils and
the ability for specific PPAR-  and -  agonists to regulate
two of their physiological functions in vitro strongly sup-
port the hypothesis that their inhibitory effects on lung in-
flammation observed in vivo in an asthma model might, in
part, be due to a direct action on eosinophils. Indeed,
PPAR-  and -  agonists induced a dose-dependent inhibi-
tion of IL-5 or eotaxin-mediated eosinophil chemotaxis,
whereas the effects of the PPAR-  agonist were fully re-
versed by cotreatment in vitro with a specific antagonist.
Eosinophil chemotaxis requires signaling through IL-5R
( c chain) or CCR3, the G protein-coupled seven trans-
membrane domain receptor for eotaxin, and leads to MAP
kinase (ERK, p38, and JNK) as well as c-jun and c-fos acti-
vation (62, 63).These factors are known targets for PPAR- 
and -  regulation (9, 23). In a similar way, ADCC reac-
tions require activation of some Fc receptors, which vary
according to the immunoglobulin isotype and the cell type.
In eosinophil-mediated ADCC toward S. mansoni larvae,
IgE and IgA are mainly involved. Fc RI and Fc RI/
CD89, their cognate receptors, share a common subunit,
FcR , whose complex signal transduction cascade leads to
MAP kinase, c-jun, c-fos (64–66), and NF- B activation
(67), which are potential PPAR targets (9). It is perhaps not
surprising that inhibition of ADCC by PPAR agonists is
weaker than for chemotaxis. Indeed, cytotoxicity is a more
complex biological process not only involving chemotaxis
but also cell–cell contacts and granule release, each of
which would only be partially inhibited by agonists.
Together, our results demonstrate that both PPAR- 
and -  directly affect eosinophil functions in vitro and are
able to regulate eosinophilia in vivo, in a murine model ofT
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asthma, where complex interactions occur. Due to re-
cently reported failure of monotherapies targeted to eosin-
ophils, such as anti–IL-5, in the treatment of eosinophilia,
asthma, and AHR (68), these nuclear receptors, which are
expressed in many immune (including T cells) and nonim-
mune cell types in the inflammatory airways, might thus
represent attractive alternative therapeutic targets for these
pathologies.
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